Allergan PLC Company Profile (NYSE:AGN)

Analyst Ratings

Consensus Ratings for Allergan PLC (NYSE:AGN) (?)
Ratings Breakdown: 5 Hold Rating(s), 16 Buy Rating(s)
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $310.63 (25.33% upside)

Analysts' Ratings History for Allergan PLC (NYSE:AGN)
Show:
DateFirmActionRatingPrice TargetActions
7/25/2016Credit Suisse Group AGInitiated CoverageOutperform$327.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016MizuhoReiterated RatingHold$232.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Bank of America Corp.Reiterated RatingBuy$287.00 -> $294.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2016Piper Jaffray Cos.Reiterated RatingHold$236.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$335.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Deutsche Bank AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Raymond James Financial Inc.Lower Price TargetOutperform$317.00 -> $275.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016SusquehannaDowngradePositive -> Neutral$345.00 -> $275.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Royal Bank Of CanadaReiterated RatingOutperform$354.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Nomura Holdings Inc.Reiterated RatingBuy$350.00 -> $330.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Barclays PLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2015BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2014Stifel NicolausDowngradeBuy -> Hold$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014Jefferies GroupReiterated RatingHold$184.00 -> $219.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014SunTrust Banks Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014William BlairDowngradeOutperform -> Market Perform$219.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Allergan PLC (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315$3.18$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$4.38$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2015Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$1.68$1.78$1.78 billion$1.79 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$1.06$1.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012$0.87$0.86ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.00$1.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.90$0.92ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2011$0.95$0.96ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2011$0.74$0.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2011$0.89$0.88ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Allergan PLC (NYSE:AGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$2.91$3.17$3.04
Q2 20161$3.29$3.29$3.29
Q3 20162$3.51$3.70$3.61
Q4 20161$4.18$4.18$4.18
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Allergan PLC (NYSE:AGN)
Annual Dividend:$0.20
Dividend Yield:0.08%
Payout Ratio:1.79% (Based on Trailing 12 Months of Earnings)
1.41% (Based on Current Year Consensus EPS Estimate)
1.16% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:-37.00% (3 Year Average)

Dividend History for Allergan PLC (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014quarterly$0.0511/20/201412/11/2014Tweet This Announcement  Share This Announcement on StockTwits
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013Tweet This Announcement  Share This Announcement on StockTwits
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Allergan PLC (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Allergan PLC (NYSE:AGN)
DateHeadline
07/25/16 02:33 PMHC Stocks Midpoint: Immune Pharmaceuticals Inc (NASDAQ:IMNP ... - share market updates (press release)
07/25/16 01:22 PMAllergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea Treatment In Adults - Allergan plc (NYSE: AGN) revealed that the Committee for Medicinal Products for Human Use (CHMP) has adopted a favorable Opinion for its TRUBERZI in the European Union. According to the company, TRUBERZI is an oral medication, which get rid of the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Allergan said that in two pivotal studies, TRUBERZI has reduced considerably two of the most bothersome symptoms of IBS-D, i.e. abdominal pain and diarrhoea, ...Full story available on Benzinga.com
07/23/16 02:20 PMStock Up Nicely This Week: Allergan plc (NYSE:AGN) - TGP
07/22/16 02:21 PMEarnings Estimates to see: Allergan plc (NYSE:AGN) - News Oracle
07/22/16 10:31 AMPuma Leaps After Hours, FDA Delays Decision On Merck's Drug, ADMP Optimistic
07/21/16 02:21 PMStocks in Focus:Valley National (VLY), Exelixis (EXEL), Allergan (AGN) - iStreetWire
07/21/16 02:21 PMHC Stocks Summary: Inovio Pharmaceuticals Inc (NASDAQ:INO), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release)
07/21/16 02:21 PMAnalyst Overview: Allergan plc (NYSE:AGN) | News Oracle - News Oracle
07/21/16 02:21 PMAllergan plc Ordinary Shares (NYSE:AGN) & M&T Bank Corporation ... - Money News (press release)
07/21/16 11:21 AMAmgen: Phase 3 Study Shows ABP 980 Could Be Biosimilar To Trastuzumab
07/21/16 11:21 AMAmgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not Ruled Out
07/21/16 11:21 AMMarket Update: Allergan Inc (NYSE:AGN) – Amgen, Allergan biosimilar found as effective as Roche cancer drug
07/21/16 08:51 AMBRIEF-Adamis Pharma provides update on license pact with Allergan - * Decision follows Adamis' receipt from FDA of a complete response letter in june
07/20/16 04:36 PM[$$] Jury Acquits Former Johnson & Johnson Unit Execs of Felony Fraud -
07/20/16 03:27 PMAllergan Files With FDA For Approval Of Oculeve Intranasal Tear Neurostimulator
07/20/16 03:27 PMCompany Update (NYSE:AGN): Actress Marisa Tomei Partners with Allergan to Raise Awareness of Chronic Dry Eye
07/20/16 10:30 AMHow has Allergan plc:(NYSE:AGN) performed recently? - The Daily Leicester
07/20/16 10:30 AMStocks Recommendation Update: Boston Scientific Corporation (NYSE:BSX) , Allergan plc. (NYSE:AGN) - Street Updates
07/20/16 10:30 AMRoss Stores, Inc. (NASDAQ:ROST) & Allergan plc Ordinary Shares (NYSE:AGN) Stocks in Focus - Money News (press release)
07/19/16 07:49 PMCompany Update (NYSE:AGN): Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator
07/19/16 07:49 PMNotable ETF Outflow Detected - IVW, V, MO, AGN
07/19/16 02:23 PMShares of Allergan plc. (AGN) Sees Large Inflow of Net Money Flow - TheFounders Daily
07/19/16 01:52 AMTeva Pharm prices $15 bln in notes to fund Allergan generics deal - TEL AVIV, July 19 (Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it successfully priced a debt offering for $15 billion worth of senior notes to help fund its acquisition of Allergan...
07/18/16 02:23 PMTrader's Roundup: Allergan plc Ordinary Shares (NYSE:AGN), Incyte Corporation (NASDAQ:INCY) - Post Registrar
07/18/16 02:23 PMMarket Movers: PTC Therapeutics, Inc.(NASDAQ:PTCT), Allergan plc Ordinary Shares(NYSE:AGN) - NYSE Journal (press release)
07/18/16 02:10 PMAllergan Files De Novo Application For Approval Of Oculeve Intranasal Tear Neurostimulator - Allergan plc (NYSE: AGN) filed the de novo application for the Oculeve Intranasal Tear Neurostimulator device with the FDA in the United States. The company quoted the regulator and said this process offered a pathway for medical devices for which general or special controls provided a reasonable assurance of safety, as well as, effectiveness. However, there is no legally marketed ...Full story available on Benzinga.com
07/18/16 08:49 AMAllergan submits marketing application in U.S. for tear neurostimulator de novo -
07/18/16 08:31 AMURGENT-Teva to sell up to seven-tranche US dollar bond Monday - NEW YORK, July 18 (IFR) - Teva Pharmaceutical is selling an up to seven-tranche US dollar bond Monday to help finance its acquisition of Allergan Generics, one of the banks managing the deal told IFR.
07/18/16 08:31 AMUPDATE 1-Teva to sell up to seven-tranche US dollar bond Monday - NEW YORK, July 18 (IFR) - Teva Pharmaceutical is selling an up to seven-tranche US dollar bond Monday to help finance its acquisition of Allergan Generics, one of the banks managing the deal told IFR.
07/18/16 07:11 AMAnalysts Are Expecting this Stock to Rise: Allergan plc (NYSE:AGN) - TGP
07/18/16 07:11 AMAnalyst Rating Fluctuations to Observe: Perrigo Company (NYSE:PRGO) , Allergan plc. (NYSE:AGN) - Street Updates
07/18/16 07:05 AMAllergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator - [PR Newswire] - DUBLIN, July 18, 2016 /PRNewswire/ -- Allergan plc (AGN) announced today that it has filed with the U.S. Food and Drug Administration (FDA) the de novo application for the Oculeve Intranasal Tear Neurostimulator device. According to the FDA, this process provides a pathway for medical devices for which general and/or special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device. This handheld stimulator was investigated for temporarily increasing tear production upon activation in patients with dry eye disease due to decreased tear production.
07/14/16 02:22 PMHC Stocks Growth: Inovio Pharmaceuticals Inc (NASDAQ:INO), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release)
07/14/16 02:22 PMTargeted Movers: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN) - Street Updates
07/14/16 02:22 PMAllergan's Teva Update: Relax - Seeking Alpha
07/14/16 07:34 AMTeva Pharma to raise $20 billion to $25 billion in bond sale next week: report - TEL AVIV (Reuters) - Teva Pharmaceutical Industries will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's generics business, the Globes...
07/14/16 07:34 AMUPDATE 1-Teva Pharm to raise $20-$25 bln in bond sale next week - report - TEL AVIV, July 14 (Reuters) - Teva Pharmaceutical Industries will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's generics business, the...
07/14/16 05:21 AMTeva Pharm to raise $20-$25 bln in bond sale next week -report - TEL AVIV, July 14 (Reuters) - Teva Pharmaceutical Industries will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's generics business, the...
07/13/16 07:54 PMWhy are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today?
07/13/16 02:25 PMStocks in Review: Express Scripts Holding Company (ESRX), Allergan plc (AGN), Ares Capital Corporation (ARCC) - iStreetWire
07/13/16 02:07 PMStocks are mostly higher on Wall Street in afternoon trading -
07/13/16 12:21 PMTeva says Allergan deal to close 'any time', expects U.S. antitrust clearance - NEW YORK/TEL AVIV (Reuters) - Teva Pharmaceutical Industries Ltd said on Wednesday it expected its $40 billion deal to buy Allergan Plc's generics business to close "at any time," even as the...
07/13/16 11:54 AMTeva says Allergan deal to close 'any time', expects US antitrust clearance - Reuters - ReutersTeva says Allergan deal to close 'any time', expects US antitrust clearanceReutersNEW YORK/TEL AVIV Teva Pharmaceutical Industries Ltd (TEVA.TA) said on Wednesday it expected its $40 billion deal to buy Allergan Plc's (AGN.N) generics business to close "at any time," even as the companies extended the deadline for completing the ...Teva Climbs as CEO Sees Robust Growth After Allergan DealBloombergTeva, Allergan Tweak Acquisition AgreementWall Street JournalTeva expects Allergan deal close any dayFiercePharmaZacks.com -24/7 Wall St. -CNBC -Investor's Business Dailyall 47 news articles »
07/13/16 11:19 AMUPDATE 3-Teva says Allergan deal to close 'any time', expects U.S. antitrust clearance - NEW YORK/TEL AVIV, July 13 (Reuters) - Teva Pharmaceutical Industries Ltd said on Wednesday it expected its $40 billion deal to buy Allergan Plc's generics business to close "at any time," even as...
07/13/16 10:30 AMTeva says Allergan deal to close 'any time' - Reuters - ReutersTeva says Allergan deal to close 'any time'ReutersTeva Pharmaceutical Industries Ltd (TEVA.TA) said on Wednesday it expected its $40 billion deal to buy Allergan Plc's (AGN.N) generics business to close "any time," even as the companies extended the deadline for completing the transaction to October ...Stocks to Watch: Diamondback Energy, Imprivata, American Airlines, Juno TherapeuticsWall Street Journal (blog)Why Teva Pharmaceuticals (TEVA) Stock Is Surging TodayTheStreet.comWhy the Teva Acquisition Proves It Is a Stock to Own for the Decade24/7 Wall St.CNBC -Washington Post -Seeking Alpha -Proactive Investors USA & Canadaall 46 news articles »
07/13/16 10:27 AMAllergan plc: Allergan to Host Second Quarter 2016 Earnings Conference Call and Webcast
07/13/16 09:47 AMWhy Traders Are Talking About Allergan, Teva, and 3 Other Stocks Today -
07/13/16 09:46 AMBRIEF-Allergan spokesman says antitrust clearance is "imminent" - * Allergan Spokesman says in emailed statement that antitrust clearance is "imminent" and agrees with Teva view that deal closing is "any time now" (Reporting By Caroline Humer)
07/02/16 08:04 AM3 Issues That Every Healthcare Investor Should Consider -
07/02/16 07:05 AM3 Large-Cap Stocks to Buy in July -

Social

About Allergan PLC

Allergan PLC logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $248.98
  • 50 Day Moving Average: $238.99
  • 200 Day Moving Average: $255.63
  • P/E Ratio: 22.18
  • P/E Growth: 1.82
  • Market Cap: $98.06B
  • Beta: 0.69
  • Current Year EPS Consensus Estimate: $14.14 EPS
  • Next Year EPS Consensus Estimate: $17.31 EPS
Additional Links:
Allergan PLC (NYSE:AGN) Chart for Monday, July, 25, 2016